VR Homework Exercises for Selective Mutism Treatment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4-13
SponsorLuuk Stapersma
About this trial
Selective mustism (SM) is an anxiety disorder that manifests in childhood. Children with Children with SM do not speak in certain social situations where this is expected of them. For example, a child may talk at home, but is afraid to speak at school. The goal of this clinical trial is to determine the efficacy of behavioral therapy for children with selective mutism (SM) combined with virtual reality (VR) homework exercises. Virtual Reality Exposure is an effective treatment for adults with anxiety disorders.
The main questions to answer are:
* Is behavioral therapy combined with VR homework exercises effective in the treatment of SM? * Which familial factors contribute to a positive treatment outcome and homework adherence?
A single-case experimental design (SCED) will be used to evaluate the efficacy of the treatment. The child's speaking behavior at baseline will be compared to the child's speaking behavior in the different phases of the intervention.
Participants will:
* Follow individual therapy sessions at school. * Practice with the VR homework exercises at least once a week. * Parents and teachers will evaluate the child's speaking behavior.
Eligibility criteria
Qualifiers
The child meets the DSM-5 criteria for SM (as a primary classification).
The child is attending primary school.
Referred to an academic center for Child and Adolescent Psychiatry (Levvel) for diagnosis and treatment of SM
Psychiatric comorbidity is permitted, given that SM is the primary treatment target.
Disqualifiers
No participating parents.
Parents do not have sufficient mastery of the Dutch language.
Parents or child have an estimated IQ below 75.
The child needs inpatient treatment.
Trial design
Treatments tested in this trial
- 'Speaking at school, a matter of doing' combined with VR homework exercises
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Luuk Stapersma
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor institution
Source ClinicalTrials.gov